The present disclosure provides a method that includes applying at least one radiofrequency saturation pulse at a frequency or a range of frequencies to substantially saturate magnetization corresponding to an exchangeable proton in the ROI to generate magnetic resonance (MR) data. The MR data is then acquired using an echo-planar imaging readout, which is configured to sample a series of gradient echo pulse trains at a series of gradient echo times and a series of spin echo pulse trains at a series of spin echo times. One or more relaxometry measurement is then computed using the MR data sampled at the gradient echo times and the spin echo times. An oxygen-weighted image is then generated using the one or more relaxometry measurement, and a pH-weighted image is generated using MR data sampled at one or more of the spin echo times or gradient echo times.

Disclosed herein are methods and systems for clinical practice of medical imaging on patients with metal-containing devices, such as implanted cardiac devices. In particular, Disclosed herein are methods and systems for improved late gadolinium enhancement (LGE) MRI for assessing myocardial viability for patients with implanted cardiac devices, i.e., cardiac pacemakers and implantable cardiac defibrillators.

Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

A process for ultrasensitive in vitro detection and/or quantification of a substance of interest in a sample is performed by detecting the luminescence emission by photoluminescent inorganic nanoparticles. The process includes (i) use of photoluminescent particles comprising a photoluminescent inorganic nanoparticle consisting of a crystalline matrix having at least 10.sup.3 rare-earth ions, and coupled to a targeting agent for the substance to be analyzed, under conditions conducive to their association with the sample substance to be analyzed; (ii) exciting the rare-earth ions of the particles by an illumination device having a power of at least 50 mW and an excitation intensity of at least 1 W/cm.sup.2; (iii) detecting the luminescence emission by the particles after single-photon absorption; and (iv) determining the presence and/or concentration of the substance by interpreting said luminescence measurement. This process can be used for in vitro diagnostic purposes and as an in vitro diagnostic kit.

Disclosed is a conjugated polymer-based nanoprobe, including a fluorescent conjugated polymer, a surface ligand, a target molecule, a near-infrared fluorescent dye and optionally a gadolinium-containing magnetic resonance contrast agent. This application also discloses a method for preparing the conjugated polymer-based nanoprobe, including: adding raw materials to an organic solvent followed by ultrasonication to obtain a mixture; and adding the mixture to ultrapure water and continuously ultrasonicating the reaction mixture. The conjugated polymer-based nanoprobe can be applied in a combined molecular imaging technique of near infrared fluorescence imaging, photoacoustic imaging and magnetic resonance imaging to effectively recognize metastatic lymph nodes and normal lymph nodes, and it can be retained in the metastatic lymph nodes for a long time, meeting the requirements for long-term observation. Moreover, the near-infrared fluorescent conjugated polymer-based nanoprobe can generate reactive oxygen under irradiation, which is suitable for the photodynamic treatment of tumors.

A method is provided that includes applying at least one radiofrequency saturation pulse at a frequency or a range of frequencies to substantially saturate magnetization corresponding to an exchangeable proton in the ROI to generate magnetic resonance (MR) data. The MR data is then acquired using an echo-planar imaging readout, which is configured to sample a series of gradient echo pulse trains at a series of gradient echo times and a series of spin echo pulse trains at a series of spin echo times. One or more relaxometry measurement is then computed using the MR data sampled at the gradient echo times and the spin echo times. An oxygen-weighted image is then generated using the one or more relaxometry measurement, and a pH-weighted image is generated using MR data sampled at one or more of the spin echo times or gradient echo times.

Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Disclosed herein are complexes of gadolinium metal, ligand and meglumine that are substantially free of non-aqueous solvents. In particular, solvent-free complexes of 1) gadopentetate dimeglumine and 2) gadoterate meglumine are disclosed and methods of their preparation are disclosed. In addition, methods are disclosed for purifying reactants, monitoring and controlling pH, quantifying the free gadolinium content, quantifying the concentration of gadolinium-ligand complex in aqueous solution, and procedures for producing a drug product in one step. The one step process eliminates the need to dry the gadolinium-ligand complex, which is typically highly hygroscopic. The one step process includes purification steps that do not require the use of non-aqueous solvents.

Disclosed herein are methods and systems for clinical practice of medical imaging on patients with metal-containing devices, such as implanted cardiac devices. In particular, Disclosed herein are methods and systems for improved late gadolinium enhancement (LGE) MRI for assessing myocardial viability for patients with implanted cardiac devices, i.e., cardiac pacemakers and implantable cardiac defibrillators.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.